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Due to the unpredictable course and heterogenous treatment response in multiple
sclerosis (MS), there is a clear need for biomarkers that reflect disease activity in the
clinical follow-up of these patients. Neurofilaments are neuron-specific components of
the cytoskeleton that can be assayed in different body compartments. They have been
explored as potential biomarkers for many years. Neurofilament light chain (NF-L) appears
the most promising biomarker in MS patients, and there is now little doubt that NF-L
should have a role in the follow-up of MS patients. Newer assays and techniques for NF-L
detection available in serum samples confirms the usefulness of NF-L as a biomarker.
Nevertheless, there is still a need for prospective studies, and studies to determine clinical
useful cut-off values. This review evaluates the strengths and weaknesses of NF-L as a
biomarker in patients with MS.
Keywords: neurofilament light (NF-L), biomarker, multiple scleorsis (MS), serum, cerebrospinal Fluid—CSF,
axonal damage
NEUROFILAMENTS—AN INTRODUCTION
Neurofilaments are cytoskeletal components of neurons that are particularly abundant in axons.
Their functions include provision of structural support and maintaining size, shape, and caliber
of the axons (1). Neurofilaments belong to the intermediate filaments family, and the triplet
comprises three subunits; neurofilament light chain (NF-L), neurofilament medium (NF-M) and
neurofilament heavy (NF-H). The nomenclature-light (∼68 kDa), -medium (∼145 kDa ),- and
heavy (∼200 kDa) refers to the molecular weight of the filaments (2, 3).
Following axonal damage in the central nervous system (CNS), neurofilament proteins released
into cerebrospinal fluid (CSF) provide an indication of axonal damage and neuronal death. The
most extensively subtype studied in this context is NF-L.
Given that neurofilaments are found in the cytoplasm of neurons, all diseases that lead to
neuronal and axonal damage can increase the CSF-levels of these proteins. In animal studies, NF-L
levels have been used as a marker of axonal damage for decades (4). In humans, neurofilaments
were first used as markers of neuronal damage in a study of 12 patients with amyotrophic lateral
sclerosis (ALS) and 11 patients with Alzheimer’s disease (5).
Subsequently, higher than control levels of neurofilaments were found in the CSF of 60 patients
with relapsing-remittingmultiple sclerosis (RRMS) (1), suggesting these proteins could also be used
as a biomarker of MS disease activity. The field of neurofilament research is rapidly expanding
and neurofilament levels are under investigation as markers of disease activity and progression
in a number of different neurological conditions including stroke (6), ALS (7), frontotemporal
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dementia (8), andMS (9). Recently, it has also been suggested that
NF-L can be associated with paraneoplastic CNS disorders (10),
and peripheral nervous system disorders (11).
Biomarkers of disease activity or disability progression are
an unmet need in several neurological conditions. A good and
reliable biomarker should say something about the stage of
the disease, the prognosis and the response to treatment. A
biomarker does not, however, need to be disease specific. It is now
clear that elevated NF-L occurs in several neurological disorders
and levels depend on age (9, 12). Nevertheless, increased NF-L
level appears to reflect ongoing neuronal damage, irrespective
of the underlying pathology, making it a potentially interesting
biomarker (9).
This review will focus on strengths and weakness of NF-L as a




MS is an inflammatory demyelinating disease of the CNS,
usually characterized by relapsing episodes of neurological
dysfunction and gradual, progressive decline. Biomarkers
reflecting ongoing neuronal damage are therefore of great value
in order to characterize the stage of disease, the prognosis and
treatment response.
The presence of neurofilament proteins in CSF has been the
subject of intense study since the finding of elevated NF-L levels
in patients with RRMS (1).
Neurofilament heavy chain has also been investigated as
a potential biomarker in MS and levels appear to correlate
with Expanded Disability Status Scale (EDSS) in patients with
RRMS and clinically isolated syndrome (CIS) (n = 102),
and also increased in patients with ongoing relapse (n =
61) (13). However, comparison of NF-H and NF-L, suggests
that NF-L discriminates better between MS (and CIS) and
controls (14).
Until recently, the greater majority of studies have focused
on detecting these proteins in CSF. Since CSF sampling requires
a semi-invasive lumbar puncture, a search for other ways of
accessing this clinically useful biomarker has focused on other
body fluids. Thus, while lumbar puncture provides a direct
approach to the CNS, access to blood is less invasive and better
tolerated by patients. Further, as neurofilaments are neuron
specific, the finding of these proteins in serum reflects leakage or
diffusion through the blood-brain barrier (BBB). NF-L can also
reach the blood through CSF drainage into venous blood (15).
Following neuronal biomarkers in blood faces several
problems, including patient specific differences in the degree
of protein leakage through the BBB (12) and the need for
sufficiently sensitive methods of detection. The single-molecule
enzyme-linked immunosorbent assay (ELISA) called single
molecule array (Simoa) (https://www.quanterix.com) can detect
very low concentrations of single enzyme-labeled proteins (16).
In fact, this powerful new technique is 126- and 25-fold
more sensitive than regular ELISA or electrochemiluminescence,
respectively (15).
A strong correlation was detected in paired serum and CSF
samples from 373 participants, (286 with MS, 45 with other
neurological conditions, and 42 healthy controls) (r = 0.62) (17).
The important fact that serum NF-L levels correlate with CSF
levels have been confirmed in several studies (9, 18, 19). Levels
in serum and plasma have also been found to correlate (12).
However, although strong positive association is found between
CSF and serum NF-L levels, the levels in serum have been
evaluated to be a 42-fold lower than in CSF (9).
NEUROFILAMENTS AS A PROGNOSTIC
BIOMARKER IN ON, CIS, AND RIS
Patients with either optic neuritis (ON), CIS or radiological
isolated syndrome (RIS) are all at risk of developing MS.
Identifying those who will convert would be of great importance
as one could more aggressively start early treatment. Studies
looking at NF-L as a predictor of conversion have provided
inconsistent results. In one study investigating multiple
biomarkers in ON patients (n = 56), increased NF-L levels were
found with increasing time from onset to CSF sampling; however,
there was no correlation between NF-L and severity of symptoms
or Gd-enhanced lesions on MRI (20). Increasing levels of NF-L
is interesting in this context as this may reflect the presence
of a “silent” axonal damage, and thus neurodegeneration.
Subsequently, studies have shown that NF-L could potentially
predict conversion to MS after ON (n = 86) (21). In addition,
CSF NF-L predicted not only visual outcome after ON, but
also seemed to have potential as a biomarker for incomplete
remission (n= 47) (22).
In a retrospective cohort of 68 patients diagnosed with CIS,
the levels of CSF-NF-L were significantly higher in patients who
later developed MS. However, NF-L was found only to be a
weak risk factor for converting to MS compared to oligoclonal
bands, and T2 lesions on MRI (23). Another study with a small
sample size (CIS patients = 38) sought to evaluate both NF-L
and N-acetylaspartate as potential biomarkers. The investigators
found higher CSF NF-L levels in both CIS-patients and those
in the early stages of MS compared to healthy controls. NF-L
levels were also related to conversion from CIS to RRMS (24).
This was also the case in a cohort of 109 CIS-patients where
converters had higher NF-L CSF levels (25), and in a study of
patients with RIS where CSF-NF-L levels were an independent
risk factor for later conversion to CIS (n = 75) (26). A smaller
2-year follow-up study of CIS patients (n = 19), showed higher
CSF-NF-L in the converters than non-converters, and NF-L
levels further classified 84% of the patients correctly in terms of
conversion/non-conversion (27).
In contrast to the above studies, an investigation of 47 patients
with CIS confirmed higher levels of CSF NF-L compared to
controls, found no difference in NF-L levels between converters
and non-converters (28). Likewise, equal CSF NF-L levels were
detected in 39 CIS patients, independent of converters or non-
converters (29). Yet another study found higher levels of serum-
NF-L in CIS-patients compared to controls (n = 92), but no
difference between what was defined as fast converters to clinical
definite MS (n= 100) and non-converters (n= 98) (30).
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Overall, NF-L appears useful as a biomarker and as a predictor
of outcome in the early clinical stages prior to definite MS.
Although the findings are not completely consistent across
studies, this does not invalidate NF-L as a biomarker as the
differences could be explained by alterations in diagnostic criteria





Studies comparing MS patients to healthy controls show that
there is a general increase inNF-L levels in patients, and a positive
correlation with relapses. Levels of CSF NF-L were almost 10
times higher in MS patients with exacerbations (n = 66) than
healthy controls (n = 50) (31), underlining the correlation
between axonal damage and relapses.
When looking at disease progression, correlation of NF-L
with EDSS is not always found (31–33). This can, however,
usually be explained by small changes in scores over time, small
patient populations, limited sensitivity and intra- and inter-rater
challenges of the scale. A small study indicated that baseline CSF
NF-L levels were higher in those patients that experienced EDSS
progression after 5 and 10 years, and was significantly associated
with conversion to SPMS (34). The NEDA (no evidence of
disease activity)-classification, which comprises EDSS, relapses
andMRI changes has also been correlated in various degrees with
NF-L (27, 35).
In RRMS and progressive MS patients, the levels of NF-L are
higher in the presence of disease activity (n = 82) (17). Higher
CSF NF-L levels compared to controls were found in primary
progressive MS (PPMS), but there was no significant difference
between PPMS (n = 21) and secondary progressive MS (SPMS)
(n = 10) (36). In cohort of 99 patients with RRMS, high levels of
CSF NF-L were associated with worse outcome and conversion to
SPMS (37).
The most objective findings in the clinical follow-up of MS
patients are changes in MRI, often evaluated on the basis of new
or enlarged T2-lesions, or T1gadolinium-enhanced lesions (Gd-
lesions). The studies of radiological changes have also shown
more consistent correlations with NF-L levels, and several studies
have reported a predictive value in NF-L in regards to one-going
lesions, and prior to lesions (9, 17, 27, 32, 38, 39).
A study of two different cohorts, one cross-sectional (n =
142) and one longitudinal (n = 246) showed generally higher
NF-L levels in patients vs. healthy controls, a correlation with
presence of relapses, worsening EDSS and MRI lesion activity
[both T2-lesions and Gd-lesions (9)]. In another follow-up study
of 39 patients, CSF NF-L correctly predicted NEDA-status after
2 years in 85% of cases (27). Both serum and CSF NF-L levels
have been found higher during relapses, and with Gd-lesions
(17). Further confirmation of these findings came from studies
showing positive correlation between serum NF-L and number
of Gd-enhanced lesions (n = 25) (38), and correlation with new
or enlarged T2-lesions and the ability to predict new Gd-lesions
(n= 85) (32).
In a cohort of 25 natalizumab-treated patients followed for
3 years, CSF-NF-L at baseline correlated with percentage brain
volume change (39), and in a retrospective CIS cohort (n =
41) NF-L correlated with changes in gray matter on MRI, and
an inverse correlation was detected between degree of MRI
normalization and NF-L (40).
The radiological correlations with NF-L indicates
the usefulness of NF-L as a marker of ongoing brain
damage in MS. NF-L is probably the most promising new




Independent of the type of disease-modifying treatment, the
majority of investigators have detected an inverse correlation
between NF-L levels and treatment. Lower levels of NF-L
were found in treated patients compared to treatment-naïve
individuals (n = 21) (38), and it has also been shown that NF-
L levels fall in follow-up studies of disease-modifying treatment
vs. no treatment (9). CSF and serum-NF-L levels are stable in
treatment-naïve patients (n = 10) or when shifted to similar
efficacy (n = 20), but fall when patients are shifted to drugs
with higher efficacy (n = 68) or when drugs are started in
the treatment-naïve (n = 50) (17). Serum NF-L levels fall after
initiation of interferon-beta (n= 85) (32), and plasmaNF-L levels
fell by 34% after 12months of fingolimod treatment (shifted from
interferon or glatiramer acetate), (n= 243) (12).
In a cohort of 92MS patients started on natalizumab, CSF
collected at baseline and after 6 or 12months showed a significant
fall in NF-L, to similar levels as healthy controls, independent
of relapses in the months before treatment startup (41). These
findings have been confirmed in other studies (33), and also
in fingolimod-treated patients vs. placebo in CSF (n = 36)
(42). In one cohort of 75 patients with clinical stable RRMS,
patients were switched from first-line injectable treatment to
rituximab and followed with CSF-NFL at baseline, at month 12
and month 24 (n = 65). NF-L levels decreased significantly 12
months after therapy shift, and as clinical and radiological signs
from relapse approached at 24 months, NF-L also increased,
but not significantly, indicating NF-L as a marker of treatment
response (43).
In a study of 59MS patients on either interferon-beta (n= 33)
or natalizumab (n= 19), or without treatment (n= 7), CSF NF-L
levels were lower in both treatment groups, but the natalizumab-
group was not significantly different from healthy controls, and
the interferon-beta NF-L levels were still significantly higher than
in the natalizumab-group (44).
In 35 patients with progressive MS, CSF NF-L levels were
evaluated after 12–24 months of mitoxantrone or rituximab
treatment and showed a significant decrease. For the patients
on disease modifying agents at baseline, the NF-L values were
already lower than the untreated group (45).
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There is now clear evidence that NF-L is a good biomarker for
treatment response in MS, especially for high efficacy drugs. This
is probably due to the better prevention of brain damage in these
treatments, underlining the role of NF-L as a marker of neuronal
and axonal damage.
NEUROFILAMENTS IN GENERAL—WHAT
NEXT AND HOW TO USE NF-L IN
CLINICAL PRACTICE?
The majority of studies that have specifically looked at NF-L have
not been performed prospectively, but retrospectively on samples
taken at varying time points in relation to clinical symptoms.
Further, study populations have often been small. Recently, a
meta-analysis of results from 15 studies verified a significant
increase of NF-L in MS patients compared to controls (46). Still,
prospective studies of much larger cohorts focusing on NF-L and
collecting baseline and follow-up data are necessary.
Before taking the Simoa-assay in to clinical use it is necessary
to compare the results of the assay between different centers (15).
Determining age-dependent cut-off values are also necessary.
A recent study aimed to estimate percentile curves for healthy
controls across different age group to be used as reference (9).
In serum samples from 246 healthy controls (median age 44.3
years), the median serum NF-L was 22.9 pg/ml (9). Of these, 87
controls had 1-year follow-up serum sample, and themedian NF-
L level increased with 1.8%, fitting with the observed positive
age-association seen in the whole cohort, where the increase
was 2.2% for each additional year (9). The median NF-L value
found in the healthy controls is in accordance with healthy
controls in a heterogenous group of studies summarized in
Table 1. Taken together, it seems that a serum NF-L value of
16–20 pg/ml is normal in healthy individuals, with age being an
increasing factor.
Interestingly, MS is not the neurological disorder that
gives the highest values of NF-L (Table 1). Both ALS (7,
47, 48) and Creutzfeldt-Jacobs disease (54) are examples
of disorders that gives especially high NF-L levels. These
disorders are characterized by neurodegeneration, and little
inflammation, which suggests that increased NF-L levels in
active MS patients, not only reflects inflammation, but also an
ongoing neurodegeneration.
NF-L cannot be used as a specific diagnostic tool in MS
but, combining NF-L with other biomarkers is of value. In
one cross-sectional study of 271 patients with clinical features
of suspected MS onset, the combination of CSF NF-L and
intrathecal immunoglobin G production had a sensitivity of 97%
for detecting RRMS patients (55).
Despite not being a MS-specific biomarker, NF-L does appear
to be a useful marker for disease activity and treatment response.
There is good evidence that NF-L has a role in everyday clinical
follow-up of MS patients, particularly as a marker of subclinical
activity in RRMS (17, 32).
The question now is how to best use NF-L in clinical practice.
A recent study showed that the early serum NF-L levels in
newly diagnosedMS can potentially predict lesion load and brain
atrophy on MRI after 10 years (56). This leads us to speculate
if one should be more aggressive in treating patients with high
serum NF-L levels at time of diagnosis, which, brings us to
the need of cut-off values to determine high, medium and low
NF-L levels.
In the follow-up of MS patients, NF-L cut-off values may
be important, i.e., does the level in healthy people have a
significance, or should we solely use the intra-individual value?
We would suggest the latter. MS patients should be monitored
TABLE 1 | Serum NF-L levels in a heterogenous group of healthy controls.
Examined disorder HC
(n)
HC age HC serum
NF-L (pg/ml)
Patient serum NF-L (pg/ml) Assay References
ALS 50 55 16.2 125 Simoa (47)
ALS 12 47 17 255/196 (early/late symptomatic phase) Simoa (7)
ALS 19 33 7.5 >54.5 ECL (48)
AD 12 86 29 42 Simoa (49)
AD dementia 193 76 34.7 AD dementia 51.0 Simoa (plasma) (18)
MCI 42.8
FTD 28 65 19.6 77.9 Simoa (50)
FTD 73 NA 3.5 31.5 ECL (8)
CIS 92 35 7.9 24.1/19.3(Converter/NC) ECL (30)
MS 22 32 11 17 Simoa (35)
MS 42 28 10.5 16.9/23 (RRMS/PMS) Simoa (17)
PN 25 NA 6.91 31.5 Simoa (11)
PSP 12 70 17.5 31 Simoa (51)
Traumatic brain injury 35 31 13 > 90 Simoa (52)
Concussion 142 NA 8.47 NA Simoa (53)
HC, healthy controls; ALS, amyotrophic lateral sclerosis; AD, Alzheimer’s disease; MCI, mild cognitive impairment; FTD, frontotemporal dementia; ECL, electrochemiluminescence; CIS,
clinically isolated syndrome; NC, non-converters; PN, peripheral neuropathies; PSP, progressive supranuclear palsy.
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with serum levels of NF-L with a time-interval of perhaps 3–6
months depending of the course of the disease. If the serum level
of NF-L increases, the clinical activity should also be evaluated
by MRI. In this way, unnecessary routine MRI screening can
be avoided and disease activity more reliably detected. In a 2-
year follow-up study of RRMS patients, an individual increase
of 10 pg/ml in serum NF-L levels gave increased risk of new
T1 gadolinium-enhanced lesions, and new T2 lesions (32). This
increase was higher than the expected age-related increase in
yearly follow-up, and might therefore indicate a level to use as an
individual cut-off.What is less clear however, is whether a similar
decrease in NF-L levels of 10 pg/ml is of any clinical interest.
Using NF-L rate of change as a marker for disease progression
is in terms with a recent study in dominant inherited Alzheimer‘s
disease, where the rate of change in NF-L levels was associated
with degree of cortical thinning on MRI (19).
In conclusion it is our opinion that serumNF-Lmeasurements
should systematically be used as prognostic biomarker to
monitor MS patients for progression, disease activity, and
treatment efficacy.
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